OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentPhase 2

VB15010

VB15010 is a small-molecule inhibitor from Zhejiang Yangli Pharmaceutical Technology Co., Ltd., in registered phase 2 trials for ovarian cancer, prostate cancer, pancreatic ductal adenocarcinoma.